Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2006

View Archived Issues

Pharmacokinetic and clinical studies of the insomnia treatment gaboxadol presented

Ceragenix enters agreement for formulation work of CSA-13 nasal ointment

Mayne Pharma acquires SuperGen's North American oncology products

Enrollment completed in follow-up study for Pollinex Quattro allergy vaccine

IND approval for Neocartilage clinical trials

Phase II SBIR grant for preclinical work on Panacea's stroke drug

QuatRx licenses 17-beta HSD-1 inhibitors from Solvay

Celera Genomics and Medarex collaborate on therapeutic antibodies in cancer

Otoprotective drug AM-111 shows benefit in acute sensorineural hearing loss

Riquent MAA accepted for review in Europe

Targeting the dopamine D3 receptor to block the reinforcing efficacy of nicotine

Johnson & Johnson report on new candidates for excessive daytime sleepiness disorders

Daily dosing with PR-171 shown safe and effective in cancer animal models

Neurocrine and Pfizer terminate indiplon collaboration

CE Mark for Cypher Select PLUS

AV-650 cleared to begin U.S. clinical trials

Phase III studies of sarizotan fail to meet primary efficacy endpoint

Recordati inlicenses Infasurf for E.U.

Proof-of-concept study begins for pagoclone in premature ejaculation

Acapodene may lower cholesterol in men receiving androgen deprivation therapy

Molecular docking studies of bosutinib identify residues essential for stable binding

Inhibition of FAAH modulates sleep patterns by increasing brain endocannabinoids

Preclinical and preliminary clinical antidiabetic profiles of the novel, DPP-IV inhibitor GRC-8200

N-5984 pharmacokinetics, safety and efficacy in healthy subjects and obese, diabetic patients

Preclinical antidiabetic efficacy and pharmacokinetics of the DPP-IV inhibitor, SYR-322

Novartis seeks Japanese approval of Xolair

Lilly files for Japanese approval of pemetrexed for malignant pleural mesothelioma

Wyeth files NDAs for women's health therapies

Recent patents impart new anticancer agents

New gastric acid antisecretory agents emerge from Altana Pharma R&D

New agents for neurological disorders subject of recent patents

Cyclohexanehexol Abeta inhibitors from Transition Therapeutics improve cognition in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...